Weston A, Caporaso N E, Taghizadeh K, Hoover R N, Tannenbaum S R, Skipper P L, Resau J H, Trump B F, Harris C C
Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
Cancer Res. 1991 Oct 1;51(19):5219-23.
Hemoglobin adducts of the activated carcinogenic aromatic amine 4-aminobiphenyl have been measured in a case-control study of lung cancer. Data obtained for lung cancer cases are compared to those obtained for controls that consisted of patients with either chronic obstructive pulmonary disease or non-pulmonary cancers. Both simple and multivariate analysis found a positive association of 4-aminobiphenyl-hemoglobin adducts with the quantity of tobacco smoked as determined by either urine cotinine or questionnaire data. No association was found between 4-aminobiphenyl-hemoglobin adducts and cancer diagnosis, and adduct levels were not related to remote tobacco use, i.e., total pack years of smoking. There was no association between the levels of adducts detected and the ability of an individual to metabolize debrisoquine (debrisoquine metabolic phenotype, CYP2D6). Whereas 4-aminobiphenyl-hemoglobin adduct levels reflected recent tobacco smoking, they were not correlated with lung cancer risk.
在一项肺癌病例对照研究中，对活性致癌芳香胺4-氨基联苯的血红蛋白加合物进行了测量。将肺癌病例获得的数据与由慢性阻塞性肺疾病患者或非肺癌患者组成的对照组获得的数据进行比较。单因素和多因素分析均发现，根据尿可替宁或问卷调查数据确定，4-氨基联苯-血红蛋白加合物与吸烟量呈正相关。未发现4-氨基联苯-血红蛋白加合物与癌症诊断之间存在关联，加合物水平与既往吸烟情况（即吸烟总量）无关。检测到的加合物水平与个体代谢异喹胍的能力（异喹胍代谢表型，CYP2D6）之间没有关联。虽然4-氨基联苯-血红蛋白加合物水平反映了近期吸烟情况，但它们与肺癌风险无关。
